ArticleOncoimmunology2013

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.

Roberta Rosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.